- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05383053
Evaluating the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity in Mild Cognitive Impairment Patients
A Single-center, Retrospective, Pivotal Study to Evaluate the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity Using MR Brain Images(Including T1 Weighted MRI and T2 FLAIR MRI) and Clinical Information (Age, Sex, APOE(apolipoproteinE) Genotype) in Mild Cognitive Impairment Patients
- Purpose of clinical trial; This clinical trial is designed to evaluate the effectiveness of 'NeuroAI' prediction accuracy compared to the amyloid PET test results by retrospectively collecting medical data of patients with mild cognitive impairment to evaluate the effectiveness of artificial intelligence-based brain image detection and diagnosis assistance software 'NeuroAI'.
- Participants; Patient with mild cognitive impairment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- Clinical recruitment; Brain MR images (T1 weighted MRI+T2 FLAIR MRI) of patients who underwent clinical diagnosis for mild cognitive impairment and performed amyloid PET tests for suspected Alzheimer's disease.
Target number of images; Total 227 (median dropout rate considered 10%; Positive*118, Negative**109)
*Positive: Amyloid PET Positive
**Negative: Amyloid PET Negative
Selection criteria; Brain MR images of image providers suitable for all of the following selection criteria may be registered in this clinical trial.
- Among those diagnosed with mild cognitive impairment (MCI) in accordance with the International Working Group on Mild Cognitive Impairment criteria, those aged 50 or older on the MRI scan date.
Those who have undergone 3D configurable 3T MRI (brain T1 weighted MRI* and T2 FLAIR MRI**) tests.
* 40-slice 2D T1 MRI scan: Plane shall be photographed with sagittal hippocampus.
** 3-slice 2D T2-FLAIR MRI scan: Plane shall be taken by axial.
FBB (F-18 Florbetaben) amyloid PET test for suspected Alzheimer's mild cognitive impairment is positive or negative.
☞ Images diagnosed with clear cerebral matrix damage (e.g., brain tumor, cerebral infarction, brain damage, normal pressure hydrocephalus, encephalitis) or mild cognitive impairment caused by metabolic diseases cannot participate in this clinical trial.
- A person who has the following clinical information* recorded. *Date of birth (or full age), gender, APOE genotype, mild cognitive impairment diagnosis date, mild cognitive impairment causative disease (Alzheimers, vascular, Louise, Parkinson's disease, frontal lobe, cerebral tumor, cerebral infarction, normal pressure head disease, encephalitis, unknown, other), MRI scan day, amyloid PET test*, FBB PET-BAPL score** **However, for FBB PET BAPL score, you may participate in this clinical trial even if the information is not recorded.
Exclusion criteria; Brain MR images of image providers that fall under any of the following exclusion criteria cannot be registered in this clinical trial.
1. MR images already used as training sets or validation sets for developing medical devices for clinical trials.
Chonnam National University Hospital and Chosun University Hospital use images not included in GARD cohort.
2. If the interval between the date of diagnosis of mild cognitive impairment and the date of MRI scan/amyloid PET examination exceeds 2 years.
3. If the tester determines that participation in the clinical trial is inappropriate because it may affect other, ethical or clinical trial results.
- Specific reasons shall be stated in the case record.
Clinical trial method;
Medical data of patients with mild cognitive impairment (brain MR images (T1 weighted MRI+T2 FLAIR MRI) and clinical information**) are continuously collected at Chosun University Hospital and Chonnam National University Hospital. However, the data used for NeuroAI learning is not collected.
☞ When moving medical data at Chosun University Hospital, an external hard drive with permission set so that only the tester can access it is used and delivered directly to the tester without using mail or other means.
*Anonymization: permanently deleting personal identification information or replacing all or part of the personal identification information with the unique identification symbol of the organization.
**Clinical information: Date of birth (or full age), gender, education level, APOE genotype, mild cognitive impairment diagnostic date, mild cognitive impairment causative disease (Alzheimers, vascular, Louise, Parkinson's disease, frontal lobe, brain tumor, cerebral infarction, normal hydrocephalus, unknown, other test days (PET).
- The collected medical data is stored in the NAS server built in the data center of Chonnam National University Hospital, a clinical trial institution. In this case, access rights should be set so that third parties other than the tester cannot access medical data.
- When medical data collection is completed, the tester checks whether the selection/exclusion criteria are met. Only brain MR images of image providers that meet all selection/exclusion criteria are enrolled in this clinical trial.
When all images are registered, the tester releases the envelope containing the random array table and gives each image a random array number according to the random array table. The release of envelopes should be implemented immediately prior to the delivery of images to clinical trial medical care managers.
- A random arrangement table is generated by a statistician in charge of a random arrangement, sealed in an envelope, and delivered to the tester.
- The tester who released the envelope shall manage the random arrangement table not to be disclosed to others during the clinical trial period.
The tester shall deliver to the clinical trial medical care manager a document containing MR images with random arrangement numbers and clinical information (birth year, gender, APOE genotype, MRI date) required for application of clinical trial medical devices.
☞ The images and documents delivered to the clinical trial medical care manager are blindfolded so that they do not include any information other than random arrangement numbers and clinical information entered into the clinical trial medical device.
The clinical trial medical device manager checks the amyloid PET positive prediction information using the clinical trial medical device. After completing the confirmation of predictive information on the last image, the clinical trial medical manager extracts and collects the predictive information of all registered images in the form of a database, and delivers it to the data manager.
☞ During the clinical trial period, other test personnel other than medical care managers set access to the data so that predictive information of medical devices for clinical trials cannot be viewed.
- For all images, the clinical trial ends when the clinical information and predictive information of the medical device for clinical trial are collected.
Clinical efficacy evaluation variable;
- First Clinical efficacy Assessment; Clinical Sensitivity(%), Clinical Specificity(%)
- Secondary Clinical efficacy Assessment; AUC of ROC Curve (Area Under the Curve of Receiver Operating Characteristic Curve), Accuracy(%)
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Gwangju, Korea, Republic of, 61469
- Chonnam National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Brain MR images (T1 weighted MRI+T2 FLAIR MRI) of patients who underwent clinical diagnosis for Mild Cognitive Impairment and performed amyloid PET tests for suspected Alzheimer's disease
N=227 (10% moderate dropout rate considered; 118 Positive*, 109 Negative**)
*Positive : Amyloid PET Positive **Negative : Amyloid PET Negative
Description
Inclusion Criteria:
Brain MR images of image providers suitable for all of the following selection criteria may be registered in this clinical trial.
- Among those diagnosed with mild cognitive impairment (MCI) in accordance with the International Working Group on Mild Cognitive Impairment criteria, those aged 50 or older on the MRI scan date.
Those who have undergone 3D configurable 3T MRI (brain T1 weighted MRI* and T2 FLAIR MRI**) tests.
* 40-slice 2D T1 MRI scan: Plane shall be photographed with sagittal hippocampus.
** 3-slice 2D T2-FLAIR MRI scan: Plane shall be taken by axial.
FBB (F-18 Florbetaben) amyloid PET test for suspected Alzheimer's mild cognitive impairment is positive or negative.
☞ Images diagnosed with clear cerebral matrix damage (e.g., brain tumor, cerebral infarction, brain damage, normal pressure hydrocephalus, encephalitis) or mild cognitive impairment caused by metabolic diseases cannot participate in this clinical trial.
A person who has the following clinical information recorded.
- Date of birth (or full age), gender, APOE genotype, mild cognitive impairment diagnosis date, mild cognitive impairment causative disease (Alzheimers, vascular, Louise, Parkinson's disease, frontal lobe, cerebral tumor, cerebral infarction, normal pressure head disease, encephalitis, unknown, other), MRI scan day, amyloid PET test*, FBB PET-BAPL score** **However, for FBB PET BAPL score, you may participate in this clinical trial even if the information is not recorded.
Exclusion Criteria:
Brain MR images of image providers that fall under any of the following exclusion criteria cannot be registered in this clinical trial.
MR images already used as training sets or validation sets for developing medical devices for clinical trials.
☞Chonnam National University Hospital and Chosun University Hospital use images not included in GARD cohort.
- If the interval between the date of diagnosis of mild cognitive impairment and the date of MRI scan/amyloid PET examination exceeds 2 years.
If the tester determines that participation in the clinical trial is inappropriate because it may affect other, ethical or clinical trial results.
- Specific reasons shall be stated in the case record.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Explore predictive values(Clinical Sensitivity, %)
Time Frame: Jun-2022 until Dec-2022
|
Clinical efficacy evaluation of the probability of predicting 'NeuroAI' as positive amyloid PET phase for MR images of positive factors as a result of amyloid PET test
|
Jun-2022 until Dec-2022
|
Explore predictive values(Clinical Specificity, %)
Time Frame: Jun-2022 until Dec-2022
|
Clinical efficacy evaluation of the probability that 'NeuroAI' does not predict positive amyloid PET phase for MR images of negative factors as a result of amyloid PET test
|
Jun-2022 until Dec-2022
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Explore predictive values(AUC of ROC Curve (Area Under the Curve of Receiver Operating Characteristic Curve))
Time Frame: Jun-2022 until Dec-2022
|
Clinical efficacy evaluation of the area below the ROC graph using the sensitivity (Y-axis) and false positive prediction (1-specificity, X-axis) of amyloid PET positive prediction presented by NeuroAI compared to the amyloid PET test results
|
Jun-2022 until Dec-2022
|
Explore predictive values(Accuracy, %)
Time Frame: Jun-2022 until Dec-2022
|
Clinical efficacy evaluation of the probability that the amyloid PET test results and the prediction information on the amyloid PET of 'NeuroAI' match
|
Jun-2022 until Dec-2022
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Byeong Chae Kim, MD, Professor (Department of Neurology,Chonnam National University Hospital)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CNUH-2022-108
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on NeuroAI
-
Fasikl Inc.RecruitingEssential TremorChina, United States